Springer Nature
Browse
12943_2015_462_MOESM1_ESM.pptx (6.79 MB)

Additional file 1: Figure S1. of PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

Download (6.79 MB)
presentation
posted on 2015-11-14, 05:00 authored by Guanzhen Yu, Wenlong Yu, Guangzhi Jin, Dongyun Xu, Ying Chen, Tian Xia, Allan Yu, Wenzheng Fang, Xiaoli Zhang, Zhaosheng Li, Keping Xie
PKM2 expression in HC tissues. A, Western blotting revealed the expression pattern of KK1, PFKB, and PKM2 in HC (T) and matched adjacent noncancerous normal tissue (N) (A). B, Graphical representation of the different expressions of KK1, PFKB, and PKM2 between N and T from (A) using Image J. C, Western blotting showed higher expressions of PKM2 in tumor (“T”) than normal (“N”) in another three cases of HC. Figure S2. PFKB expression and HC patient survival. Kaplan-Meier survival curves for patients with HC according to expression of PFKB. DFS (A) and OS (B) did not differ significantly between HC patients with low or high PFKB expression. Cum, cumulative. Figure S3. Subgroup survival analysis of PKM2 expression in HC patients according to TNM category. A, patients with stage I or II HC and high PKM2 expression had a shorter median time to recurrence than did those with stage I or II HC but without PKM2 overexpression. B, patients with stage III or IV HC and high PKM2 expression had a significantly shorter median time to recurrence than did patients with stage III or IV HC but with low PKM2 expression. C, the median OS duration was significantly worse in patients with stage I or II HC and PKM2 expression than in those with stage I or II HC but with low PKM2 expression. D, the median OS duration was significantly worse in patients with stage III or IV HC and PKM2 expression than in those with stage III or IV HC but with low PKM2 expression. Cum, cumulative. Figure S4. Representative MS/MS spectrum showing the peptide of PKM2 protein. A, the intensity of repots ions of precursor peptides indicating protein expression levels. N, normal bile duct tissue. B, MS/MS spectra demonstrating identified sequences of the peptide LAPITSDPTEATAVGAVEASFK leading to identification of PKM2. Figure S5. Localization of PKM2 expression in HC cells. A and B, cytoplasmic staining for PKM2 in well/moderately differentiated cancer cells. C and D, cytoplasmic and nuclear staining (arrow) for PKM2 in poorly differentiated cancer cells. Figure S6. Xenograft models of HC. A and B, tumor cells were treated with either control shRNA or PKM2 shRNA and orthotopically implanted into nude mice as described in Materials and Methods. Tumor cells with high PKM2 expression had a higher frequency of lymph node metastasis and liver lesions than did cells with low PKM2 expression (red arrows). C, tumors with downregulated PKM2 expression had lower SDC2 expression than did those with high PKM2 expression. Figure S7. Kaplan-Meier survival curves for patients with HC according to SDC2 expression. A, patients with high SDC2-expressing tumors had a shorter median DFS duration than did patients with low SDC2-expressing tumors. B, the median OS duration in patients with high SDC2 expression did not differ significantly from that in patients with low SDC2 expression. Cum, cumulative. Figure S8. Effect of metformin treatment on tumor cell growth. A, Metformin inhibited the ability of cell proliferation of RBE cells in vitro as determined by using the CCK8 assay. B, Representative photos of HC protein staining positivity and expression pattern of IHC staining were presented. (PPTX 6948 kb)

Funding

G. S. Hogan Gastrointestinal Research Fund

History